Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 881Neoplasms 668Prostatic Neoplasms 455Lung Neoplasms 368Colorectal Neoplasms 335Carcinoma, Non-Small-Cell Lung 320Leukemia, Myeloid, Acute 257Pancreatic Neoplasms 224Brain Neoplasms 210Multiple Myeloma 204Neoplasm Metastasis 201Carcinoma, Hepatocellular 184Head and Neck Neoplasms 183Glioblastoma 170Precursor Cell Lymphoblastic Leukemia-Lymphoma 169Melanoma 159Ovarian Neoplasms 158Squamous Cell Carcinoma of Head and Neck 152Recurrence 139Rectal Neoplasms 137Hematologic Neoplasms 130Sarcoma 126Uterine Cervical Neoplasms 124Stomach Neoplasms 118Carcinoma, Renal Cell 118Triple Negative Breast Neoplasms 116Glioma 116Motor Activity 105Urinary Bladder Neoplasms 100Myelodysplastic Syndromes 99

Interventions

trifluridine tipiracil drug combination 1Nivolumab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Microsatellite-stable Colorectal Cancer × 90 days × Clear all
NCT07011550 2026-03-20

Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer

M.D. Anderson Cancer Center

Phase 2 Suspended
7 enrolled
Gastrointestinal

Microsatellite-stable Colorectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡